The peripheral nerve: A neglected topic in Charcot's neurological work.

Jean-Martin Charcot (1825-1893) did not show much interest in the peripheral nervous system and its associated pathologies. He found it difficult to place the peripheral nerve within his classification of disorders; it appeared to be an exception to his theories. Even the pathology that he described in 1886 with Pierre Marie (1853-1940), at the same time as Henry Tooth (1856-1925), and which is now known as Charcot-Marie-Tooth neuropathy, was considered by Charcot to be a potential myelopathy.

Charcot and Léon Daudet and Charcot: A missed love story?

Biographies, articles, and meetings devoted to the founder of modern neurology, Jean-Martin Charcot, are typically dithyrambic, if not hagiographic. It seems that the striking professional and familial qualities of Charcot have erased any other characteristic of the person, and scratches on the Master image commonly have not been well accepted. With this in mind, it is interesting to present and evaluate the rather negative opinions on Charcot by the famous French writer Léon Daudet, who initially was very close to the Charcots through his father, Alphonse Daudet, and who wrote rather extensively on Charcot in his diary and memoirs.

Charcot's international visitors and pupils from Europe, the United States, and Russia.

The foundation by (1825-1893) of the Salpêtrière School in Paris had an influential role in the development of neurology during the late-nineteenth century. The international aura of Charcot attracted neurologists from all parts of the world. We here present the most representative European, American, and Russian young physicians who learned from Charcot during their tutoring or visit in Paris or Charcot's travels outside France.

Effectiveness, Safety and Patients' Satisfaction of Nabiximols (Sativex) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study.

Cannabinoid oro-mucosal spray nabiximols is approved for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other antispastic medications. Few real-world data are available on the effectiveness, safety and patients' satisfaction in MS patients treated with nabiximols as monotherapy. To investigate the effectiveness, tolerability and satisfaction of nabiximols in a real-life multicentric Swiss cohort as monotherapy or with stable doses of other antispastic medications, and explore clinical features which may predict treatment response.